Top Markets
Coin of the day
IntegraGen SA IntegraGen SA

IntegraGen SA

ALINT
株式のランク #19673
IntegraGen SA provides human genome analysis services for academic researcher... IntegraGen SA provides human genome analysis services for academic researcher and life sciences companies in France. Its genomic services include transcriptomics, epigenomics, DNA sequencing, NGS testing for cancer research, and SNP genotyping. The company offers clinical research services, such as clinical grade sequencing and pharmacogenomics; basic and human genetic research; agrigenomic services, including crop and livestock genotyping and high-throughput sequencing for crops and livestock; and microbial genomics services comprising whole-genome microbial sequencing and microbial transcriptomics. It also provides MERCURY, an online biological interpretation tool for oncology intended to assist pathologists and oncologists in transforming raw data obtained through high-throughput sequencing into a molecular report for translational and clinical research use; SIRIUS, a cloud-based software tool that enables researchers to analyze whole genome, whole exome, and gene panel sequencing data; Galileo, a cloud-based app for dynamic exporation of RNA-Seq expression data; and GeCo, a genomic consulting service that offers researchers with access to biostatistics and bioanalytics experts. IntegraGen SA was founded in 2000 and is headquartered in Évry, France. IntegraGen SA is a subsidiary of OncoDNA SA.
株価
$0.20876331
時価総額
$1.38M
変化(1日)
1.15%
変化(1年)
-64.84%
FR
取引 IntegraGen SA (ALINT)

カテゴリー

IntegraGen SA(ALINT)のP/E比率
July 2026 時点のP/E比率 TTM -0.44
IntegraGen SA の最新の財務報告および株価によると、現在の P/E (TTM) は -0.44 です。2023 年末時点での P/E は -34.49 でした。
IntegraGen SA の P/E 比率の履歴(2008 〜 2026)
各年末のP/E比率
P/E比率 変化
2026 (TTM) -0.44 -97.03%
2024 -14.87 -56.90%
2023 -34.49 -98.49%
2022 -2.29K -580.43%
2021 475.99 -1,410.17%
2020 -36.33 58.02%
2019 -22.99 265.16%
2018 -6.30 -66.77%
2017 -18.95 83.80%
2016 -10.31 -30.43%
2015 -14.82 -41.54%
2014 -25.35 240.82%
2013 -7.44 -55.44%
2012 -16.69 12.86%
2011 -14.79 89.29%
2010 -7.81 -20.84%
2009 -9.87 10.70%
2008 -8.92 0.00%
類似企業や競合他社のP/E比率
企業 P/E比率 P/E比率の差
11.47 -2,699.77%
DK
29.20 -6,721.81%
US
14.66 -3,424.54%
US
31.95 -7,345.17%
BE
51.86 -11,859.75%
NL
P/E比率の読み方

株価収益率(P/E Ratio)は、企業の株価と1株あたり利益の関係を示します。
低いが正のP/Eは、現在の評価額に対して高い利益を上げている企業を示し、割安と見なされる可能性があります。高い負の(0に近い)P/Eは、損失が大きいことを示します。

P/Eが30を超えるか、負である企業は一般に「成長株」と見なされ、投資家は将来的な成長または黒字化を期待しています。

10未満の正のP/Eを持つ企業は一般に「割安株」と見なされ、既に収益性が高いが成長の余地は小さいと見なされます。